![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naïve participants from phase 3 clinical trials
|
|
|
Ernest Asante-Appiah, Merck & Co., Inc
IAC 2020 Virtual July 6-10 SF
Reported by Jules Levin
![0707201](../images/070720/070720-3/0707201.gif)
![0707202](../images/070720/070720-3/0707202.gif)
![0707203](../images/070720/070720-3/0707203.gif)
![0707204](../images/070720/070720-3/0707204.gif)
![0707205](../images/070720/070720-3/0707205.gif)
![0707206](../images/070720/070720-3/0707206.gif)
![0707207](../images/070720/070720-3/0707207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|